Mark Stapley
Marc Stapley plans to leave Illumina, effective Jan 1., 2019. Stapley is currently executive VP of strategy and corporate development at Illumina, where he is responsible for corporate strategy, corporate and business development, and infrastructure. He joined Illumina in 2012 and has held multiple roles with the firm, including as CFO and chief administrative officer. Prior to joining Illumina, he was senior VP of finance at Pfizer.
Jim Mullen
Jim Mullen has been elected to the board of directors of Thermo Fisher Scientific, bringing the total number of board members to 12. He was previously the CEO of Patheon, which Thermo Fisher acquired last year. Prior to that, Mullen served as president and CEO of Biogen Idec. Mullen holds a bachelor of science degree in chemical engineering from Rensselaer Polytechnic Institute and a master's degree in business from Villanova University.
Scott Nicholson, Cory Dunn
Biocept has appointed Scott Nicholson as its VP of sales in the US and Cory Dunn as its VP of marketing. Nicholson has 24 years of experience in the medical laboratory industry with a focus in oncology for the physician and hospital markets. He has served as a sales manager, executive, district manager, and regional manager in prior positions. Most recently, Nicholson was VP of sales at GenomeDx, where he led the commercialization effort for the firm's Decipher tests.
Dunn has over 15 years of commercial marketing experience, specializing in diagnostic testing services for oncology. She most recently served as VP of commercial marketing at GenomeDx, where she led the launch, commercial marketing, and product life cycle management of the Decipher suite of tests. Prior to GenomeDx, Dunn oversaw the marketing efforts for Plus Diagnostics' Gastroenterology, Dermatology and Hematology-Oncology product lines. She holds post graduate science and education degrees from the University of California, San Diego and Stanford University, respectively.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.